Stereotaxis, Inc.
$1.98
▲
1.08%
2026-04-21 09:39:03
www.stereotaxis.com
ASE: STXS
Explore Stereotaxis, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$192.55 M
Current Price
$1.98
52W High / Low
$3.59 / $1.74
Stock P/E
—
Book Value
$0.14
Dividend Yield
—
ROCE
-73.98%
ROE
-1.44%
Face Value
—
EPS
$-0.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
131
Beta
1.42
Debt / Equity
29.04
Current Ratio
1.51
Quick Ratio
1.09
Forward P/E
-15.27
Price / Sales
5.63
Enterprise Value
$179.11 M
EV / EBITDA
-9.74
EV / Revenue
5.53
Rating
Strong Buy
Target Price
$4.2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Jin Medical International Ltd. | $2.08 | 13.77 | $16.4 M | — | 2.06% | 4.75% | $19.7 / $1.64 | $3.79 |
| 2. | Nephros, Inc. | $3.07 | 27.37 | $32.68 M | — | 10.54% | 12.71% | $6.42 / $1.64 | $0.96 |
| 3. | Stevanato Group S.p.A. | $15.86 | 26.32 | $4.33 B | 0.39% | 9.9% | 9.67% | $28 / $12.89 | $6.28 |
| 4. | Milestone Scientific Inc. | $0.29 | — | $23.33 M | — | -155% | -1.32% | $1.11 / $0.22 | $0.04 |
| 5. | Pro-Dex, Inc. | $53.3 | 15.38 | $174.44 M | — | 22.96% | 30.87% | $70.26 / $23.47 | $12.97 |
| 6. | Anbio Biotechnology | $26.98 | 380.56 | $3.88 B | — | 11.61% | 27.05% | $55.65 / $6.05 | $0.63 |
| 7. | Bionano Genomics, Inc. | $1.31 | — | $14.53 M | — | -65.83% | -66.15% | $5.5 / $1.06 | $4.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 8.64 M | 7.46 M | 8.8 M | 7.47 M | 6.34 M | — |
| Operating Profit | -5.65 M | -6.56 M | -3.98 M | -5.93 M | -7.63 M | — |
| Net Profit | -5.53 M | -6.46 M | -3.83 M | -5.82 M | -7.51 M | — |
| EPS in Rs | -0.06 | -0.07 | -0.04 | -0.06 | -0.08 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 32.38 M | 26.92 M | 26.77 M | 28.15 M |
| Operating Profit | -22.11 M | -24.74 M | -21.84 M | -18.78 M |
| Net Profit | -21.64 M | -24.05 M | -20.71 M | -18.29 M |
| EPS in Rs | -0.22 | -0.25 | -0.21 | -0.19 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 52.25 M | 46.72 M | 41.91 M | 53.41 M |
| Total Liabilities | 33.53 M | 35.29 M | 19.99 M | 21.48 M |
| Equity | 18.72 M | 11.43 M | 21.92 M | 31.93 M |
| Current Assets | 33.85 M | 26.44 M | 33.27 M | 43.25 M |
| Current Liabilities | 22.36 M | 21.6 M | 13.25 M | 14.29 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.69 M | -8.5 M | -9.14 M | -8.41 M |
| Investing CF | -0.09 M | 0.07 M | 19.77 M | -22.09 M |
| Financing CF | 14.76 M | 0.3 M | 0.08 M | 0.22 M |
| Free CF | -13.78 M | -8.53 M | -9.51 M | -10.79 M |
| Capex | -0.09 M | -0.03 M | -0.37 M | -2.38 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 0.55% | -4.89% | — | — |
| Earnings Growth % | -16.09% | -13.24% | — | — |
| Profit Margin % | -89.33% | -77.37% | -64.99% | — |
| Operating Margin % | -91.91% | -81.58% | -66.71% | — |
| Gross Margin % | 54.22% | 55.51% | 65.62% | — |
| EBITDA Margin % | -88.31% | -79.35% | -65.18% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.